Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NYSE:TARO

Taro Pharmaceutical Industries (TARO) Stock Price, News & Analysis

About Taro Pharmaceutical Industries Stock (NYSE:TARO)

Key Stats

Today's Range
$42.97
$42.97
50-Day Range
$42.20
$42.99
52-Week Range
$32.67
$45.76
Volume
N/A
Average Volume
45,199 shs
Market Capitalization
$1.62 billion
P/E Ratio
29.84
Dividend Yield
N/A
Price Target
$43.00
Consensus Rating
Hold

Company Overview

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug chains, food chains, hospitals, mass merchandisers, e-commerce stores, and other direct consumers, as well as healthcare institutions and private pharmacies. The company was incorporated in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Alkaloida Chemical Company Zrt. As of June 30, 2023, Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Sun Pharmaceutical Industries Limited.

Taro Pharmaceutical Industries Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
14th Percentile Overall Score

TARO MarketRank™: 

Taro Pharmaceutical Industries scored higher than 14% of companies evaluated by MarketBeat, and ranked 936th out of 1,001 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Taro Pharmaceutical Industries is 29.84, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 135.98.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Taro Pharmaceutical Industries is 29.84, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 143.06.

  • Price to Book Value per Share Ratio

    Taro Pharmaceutical Industries has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for TARO.
  • Dividend Yield

    Taro Pharmaceutical Industries does not currently pay a dividend.

  • Dividend Growth

    Taro Pharmaceutical Industries does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for TARO.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Taro Pharmaceutical Industries this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Taro Pharmaceutical Industries insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.80% of the stock of Taro Pharmaceutical Industries is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    91.40% of the stock of Taro Pharmaceutical Industries is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Taro Pharmaceutical Industries' insider trading history.
Receive TARO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Taro Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

TARO Stock News Headlines

Protect Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
See More Headlines

TARO Stock Analysis - Frequently Asked Questions

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced its quarterly earnings results on Thursday, October, 28th. The company reported $0.66 earnings per share for the quarter, missing analysts' consensus estimates of $1.02 by $0.36. The firm earned $131.99 million during the quarter, compared to analyst estimates of $153.23 million. Taro Pharmaceutical Industries had a net margin of 8.56% and a trailing twelve-month return on equity of 3.75%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Taro Pharmaceutical Industries investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

Last Earnings
10/28/2021
Today
10/23/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Employees
1,554
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$43.00
High Stock Price Target
$43.00
Low Stock Price Target
$43.00
Potential Upside/Downside
+0.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$53.87 million
Pretax Margin
13.14%

Debt

Sales & Book Value

Annual Sales
$629.18 million
Cash Flow
$2.38 per share
Book Value
$47.70 per share

Miscellaneous

Free Float
32,400,000
Market Cap
$1.62 billion
Optionable
Optionable
Beta
0.56
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NYSE:TARO) was last updated on 10/24/2024 by MarketBeat.com Staff
From Our Partners